علاج سرطان الدم/الليمفوما من الخلايا التائية لدى البالغين في الشكل اللوكيمي العدواني

References

DOI: 10.1111/bjh.17951

• Patients with aggressive leukaemic form of ATLL should be offered high-dose AZT/IFN-a and non-responders should be switched to chemotherapy (GRADE 1C).
• In the aggressive form of acute ATLL higher initial doses of AZT/IFN-a are used before reducing to maintenance dosing in responding patients.
• G-CSF support is usually required.
• All potentially eligible patients should be offered allo-HSCT to consolidate response (GRADE 1B).
• For patients ineligible for allo-HSCT, consider maintenance therapy with AZT/IFN-a.
• If AZT/IFN-a is poorly tolerated, consider oral low-dose etoposide-containing chemotherapy (GRADE 1C).
• Consider addition of an integrase inhibitor (e.g. raltegravir) to transplant conditioning protocols to prevent neo-infection of donor stem cells (GRADE 2D).